Boston Scientific (NYSE:BSX) said today that it won pre-market approval from the FDA for a pair of ablation catheters that use the 3D cardiac mapping technology it bought from Rhythmia Medical back in 2012. Marlborough, Mass.-based Boston Scientific said the federal safety watchdog gave the green light to its IntellaNav XP and IntellaNav MiFi XP mapping and ablation […]
Rhythmia Medical Inc.
Samsung Electronics Co. Ltd. (KSE:005930.KS) launched a new corporate identity for medical products created through its collaboration with Korea based ultrasound equipment maker Medison Co.
The combined group, Samsung Medison, has a goal of becoming one of the world’s top 4 diagnostic ultrasound firms and, by 2020, aims to have 10,000 employees, according to the company.
Masimo Corp. (NSDQ:MASI) announced positive results from a study on its carbon monoxide (CO) poisoning screening technology.
The Irvine, Calif.-based company reported that an independent study demonstrated that noninvasive Masimo carboxyhemoglobin (SpCO) measurements provide an "effective means for screening at-risk populations for CO poisoning" with "acceptable bias and precision" compared to invasive blood gas analysis. The results were published in the April issue of Annals of Emergency Medicine.
Rhythmia Medical Inc. drummed up $5 million in equity from eight investors, according to a Securities & Exchange Commission filing.
The Burlington, Mass.-based developer of medical devices for treating arrhythmia is still $2 million shy of its $7 million target for this funding round, according to the filing.
Rhythmia Medical Inc. raised nearly $2.7 million in a third-round equity sale to a group of 14 investors, according to new securities documents.
Burlington, Mass.-based Rhythmia, founded in 2004 by two Israeli entrepreneurs, is developing medical devices able to quickly map the electrical activity of the heart and pinpoint catheter ablation procedures.